Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
TRIUMPH-4 (December 2025): Topline results from the Phase 3 TRIUMPH-4 investigational trial evaluating the triple hormone receptor agonist in adults with obesity or overweight and knee osteoarthritis, without diabetes, met all primary and key secondary endpoints, with substantial reductions in body weight and improvements in knee pain and physical function also observed
Recommended articles Effect of Telmisartan and Quercetin in 5 Fluorouracil-Induced Renal Toxicity in Rats Ali HH, Ahmed ZA, Aziz TA Journal of Inflammation Research 2022, 15:6113-6124 Published Date: 7 November 2022
The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting
Weight loss of 710% of body weight has been shown to improve liver histology in NAFLD (as per NICE NG49 guidance), whilst glutathione's benefits remain unproven
Small RNA-big impact: exosomal miRNAs in mitochondrial dysfunction in various diseases
US$ 28.25
US$ 25.78
US$ 29.57
US$ 23.20
US$ 24.09
